J&J's quarterly sales have climbed with few setbacks, while Pfizer's have swung between $13.7 billion and $17.8 billion over eight quarters.
Johnson & Johnson has agreed to buy Ollin Biosciences, a clinical-stage biopharmaceutical company developing therapies for serious eye diseases.
Johnson & Johnson is in talks to buy Ollin Biosciences for up to $3.4B, including $2.2B upfront and $1.2B in potential milestones.
Nov 15 () - Johnson & Johnson could announce a deal as soon as Monday to buy Texas-based biotech Ollin Biosciences for up to $3.4 billion, the Financial Times said, citing people familiar with the matter.
Detailed price information for Nvidia Corp (NVDA-Q) from The Globe and Mail including charting and trades.
Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
Johnson & Johnson’s prostate cancer immunotherapy showed strong early PSA declines in a small trial.
Johnson & Johnson (JNJ) says plaque psoriasis pill Icotyde succeeded in a Phase 3 trial for psoriatic arthritis. Read more here.
Johnson & Johnson (NYSE: JNJ) today announced new patient experience findingsa from the Phase 2 DAHLIAS study of nipocalimab in Sjögren's disease (SjD), a chronic, systemic autoantibody-driven disease affecting approximately four million people worldwide.1 The results show that mouth dryness is the symptom improvement that matters most to patients,2 complementing previously reported Phase 2 study results on increased saliva production in patients who received nipocalimab.3 This was also the most
Some companies will perform pretty well regardless of whether or not interest rates rise.
This is the newest page. Registered accounts read further back.